Team 27
A Novel, Hand-Held, Fast, Small Volume Blood Diagnostic Device to Correlate Biomarkers with Mild Cognitive Impairment and Alzheimer’s Disease
Team Members:
A Novel, Hand-Held, Fast, Small Volume Blood Diagnostic Device to Correlate Biomarkers with Mild Cognitive Impairment and Alzheimer’s Disease
Team Members:
Haley Ellis
Jason Mayo
Sean Stanek
Jennifer Wong
Team Mentors:
Dr. Jessica Weaver, PhD - Arizona State University, SBHSE
Dr. Apollo Arquiza, PhD - Arizona State University, SBHSE
Dr. Nicole Herbots, PhD - Alzheimer Bio-Sensors/Arizona State University
YouTube Link:
View the video link below before joining the zoom meeting
Zoom Link:
https://asu.zoom.us/j/82105496656
Abstract
Nearly 44 million people worldwide suffer from Alzheimer’s Disease (AD), a progressive, neurodegenerative disease that destroys memories and critical brain functions. Early detection during the Mild Cognitive Impairment (MCI) phase as a precursor leading to AD is critical as there are no cures when AD fully develops, only symptomatic treatments and therapies.
Currently, AD diagnostic methods are very limited. There are no standardized nor portable devices on the market to measure methylglyoxal (MGO), which is a limitation to assess its potential in treating AD. Hence, the present work aims to prototype a novel, hand-held, fast, inexpensive, and accurate Small Volume Blood Diagnostics (SVBD) device, Alz-BioSsTM, to test for the presence MCI leading to AD via MGO levels and help monitor the impact of treatments on a regular basis. Alz-BioSs has demonstrated proof of concept for the device.
MGO is a biomarker of interest because of the role that MGO, or any MGO-derived advanced glycation end products, play in the pathogenesis of AD. Semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) is expressed in vascularized tissues, including the brain; furthermore, the presence of SSAO/VAP-1 enzyme has been found in the brains of AD patients. SSAO/VAP-1 is responsible for the conversion of proteins into MGO; therefore, MGO could measure vascularized brain tissue, a common symptom of both MCI and AD.
The IPDT demonstrated that a simple working LED-Photodetector Optical System can replace an expensive light spectrometer and has continuous design work on the optical detection system. They have also demonstrated that optical detection of the bio-reagent o-phenylenediamine (OPD) and gold nanoparticles (AuNP) used for detecting clinical levels of MGO is possible with 0.05-0.2mL drops instead of 2mL vials.
